Debanjana Chatterjee
Stock Analyst at Jones Trading
(2.17)
# 2,722
Out of 4,869 analysts
10
Total ratings
66.67%
Success rate
2.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Initiates: Buy | $24 | $10.65 | +125.35% | 1 | Jun 17, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $15 → $27 | $8.72 | +209.63% | 2 | Jun 6, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Buy | $39 | $25.73 | +51.57% | 1 | Apr 28, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $30 | $12.15 | +146.91% | 2 | Mar 26, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Buy | $23 | $4.76 | +383.19% | 1 | Mar 13, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Hold | n/a | $15.01 | - | 1 | Dec 11, 2024 | |
| PHVS Pharvaris | Initiates: Buy | $46 | $17.06 | +169.64% | 1 | Sep 19, 2024 | |
| NTLA Intellia Therapeutics | Initiates: Buy | $41 | $9.20 | +345.65% | 1 | Sep 17, 2024 |
Theravance Biopharma
Jun 17, 2025
Initiates: Buy
Price Target: $24
Current: $10.65
Upside: +125.35%
Sagimet Biosciences
Jun 6, 2025
Maintains: Buy
Price Target: $15 → $27
Current: $8.72
Upside: +209.63%
Tvardi Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $39
Current: $25.73
Upside: +51.57%
KalVista Pharmaceuticals
Mar 26, 2025
Maintains: Buy
Price Target: $30
Current: $12.15
Upside: +146.91%
Contineum Therapeutics
Mar 13, 2025
Initiates: Buy
Price Target: $23
Current: $4.76
Upside: +383.19%
Spyre Therapeutics
Dec 11, 2024
Initiates: Hold
Price Target: n/a
Current: $15.01
Upside: -
Pharvaris
Sep 19, 2024
Initiates: Buy
Price Target: $46
Current: $17.06
Upside: +169.64%
Intellia Therapeutics
Sep 17, 2024
Initiates: Buy
Price Target: $41
Current: $9.20
Upside: +345.65%